Clinical trials: Clopidogrel, Poor Metabolism of
Peripheral Arterial Disease, Clopidogrel, Poor Metabolism of
Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease
This study evaluates the effects of Aspirin and thienopyridine resistance in relation to clinical cardiovascular outcomes as the genetic predictors of, and outcomes associated with aspirin and thienopyridine resistance in…
- Trial name
- NCT03174990
- Where
- United States
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Adverse Drug Events, Adverse Drug Reactions
YouScript IMPACT Registry
This multicenter observational study aims to investigate the benefits of providing pharmacogenetic testing with the YouScript Personalized Prescribing System which includes a clinical decision support tool and individualized…
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- IMPACT (NCT02191358)
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- Genelex Corporation
Heart Diseases, Coronary Disease
CES1 Carriers in the PAPI Study
This study builds, in part, upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396).
- Conditions
- Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases
- Trial name
- NCT03188705
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Clopidogrel, Poor Metabolism of, Carotid Stenosis
Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)
Spontaneous prospective observational multicentre pharmacological study that aims to evaluate whether, from a statistical point of view, there is a significant difference between the use of Ticagrelor in "non-responders" patients…
- Trial name
- NCT05566301
- Testing
- Clopidogrel, Ticagrelor
- Where
- Italy
- Volunteers
- 1,140 people
- Sponsor
- IRCCS Policlinico S. Donato
CLOPIDOGREL, POOR METABOLISM of (Disorder)
Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS
Clopidogrel, in addition to aspirin, is the cornerstone of therapy in patients suffering from Acute coronary syndrome. However, the platelet inhibitory response to clopidogrel varies substantially among individuals.
- Trial name
- GI-CT (NCT02048228)
- Testing
- genotyping guided therapy Ticagrelor, Clopidogrel, standard therapy clopidogrel
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Hip Fractures, Clopidogrel, Poor Metabolism of
Aggregometry in Elderlies With Hip Fracture and Receiving Clopidogrel
In elderly patients, hip fracture should be surgically treated within 48 hours from admission, since its deferral worsens the mortality.
- Conditions
- Hip Fractures, Clopidogrel, Poor Metabolism of, Anesthesia
- Trial name
- NCT04642209
- Testing
- Aggregometry
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- University Magna Graecia
Coronary Artery Disease, Clopidogrel, Poor Metabolism of
PTRG-DES Consortium
The PTRG-DES consortium is a coalition composed of multi-center, real-world registries including CAD patients treated with DES in South Korea.
- Conditions
- Coronary Artery Disease, Clopidogrel, Poor Metabolism of, Platelet Dysfunction, Stent Thrombosis
- Trial name
- PTRG (NCT04734028)
- Testing
- Clopidogrel Tablets
- Where
- South Korea
- Volunteers
- 13,160 people
- Sponsor
- Gyeongsang National University Hospital
Clopidogrel, Poor Metabolism of, Ischemic Stroke
Clopidogrel Resistance in Stroke Patients From Different Ethnicities
Clopidogrel is an anti-platelet agent used to inhibit blood clots. Variation in response to clopidogrel has been reported among different population and may lead to reoccurring ischemic events.
- Trial name
- NCT03806894
- Testing
- Quantification of platelet aggregation
- Volunteers
- 300 people
- Sponsor
- Ziv Hospital
Myocardial Ischemia, CLOPIDOGREL, POOR METABOLISM of (Disorder)
Genotyping Influences Outcome of Coronary Artery Stenting
This study evaluated epidemiology and clinical outcome of clopidogrel related various genotyping in Korean patients who had undergone percutaneous coronary intervention as a all comer registry form.
- Trial name
- GENIUS (NCT02707445)
- Testing
- Clopidogrel
- Volunteers
- 5,000 people
- Sponsor
- Korea University Anam Hospital
Coronary Artery Disease, Clopidogrel, Poor Metabolism of
Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity
With the widespread use of clopidogrel, resistance to clopidogrel has been attracting increasing attention, and emerged as a new challenge adversely affecting patients clinical risk and outcome.
- Trial name
- NCT03062462
- Testing
- Clopidogrel, ticagrelor
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Cerebral Infarction, Clopidogrel,Poor Metabolism of (Disorder)
The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized and Cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction
The investigators team had found that the presence of dynamic changes of Clopidogrel resistance are not associated with genetic factors.
- Trial name
- NCT02411903
- Testing
- atorvastatin and clopidogrel, rosuvastatin and clopidogrel
- Volunteers
- 160 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
Peripheral Artery Disease, Clopidogrel, Poor Metabolism of
The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.
- Conditions
- Peripheral Artery Disease, Clopidogrel, Poor Metabolism of, Peripheral Vascular Disease, Artery Disease
- Trial name
- NCT04007055
- Testing
- Point of care screening for HPR, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Marissa Jarosinski